NEWS

Sant Pau and the Tibidabo Amusement Park Join Forces to Promote Scientific Vocations and Scientific Dissemination with a Gender Perspective

The Sant Pau Research Institute (IR Sant Pau) and the Tibidabo Amusement Park have signed a collaboration agreement to promote the dissemination of gender-focused research and encourage scientific vocations among the young, with the central theme being the celebration of the International Day of Women and Girls in Science in February 2025. This agreement demonstrates the shared commitment of both entities to promote a more equitable society aware of the importance of science and the role of women in this field and to drive a project that combines science, gender perspective, fun, and outreach.

més…


Sant Pau researchers discover a new gene that causes ALS

Researchers from the Neuromuscular Diseases Group and the Dementia Neurobiology Group of the Sant Pau Research Institute (IR Sant Pau) and the Memory Unit of the Sant Pau Hospital, led by neurologist Dr. Ricard Rojas-García, have identified a new mutation in the ARPP21 gene that could be the cause of Amyotrophic Lateral Sclerosis (ALS), a devastating neurodegenerative disease.

més…


Sant Pau Lays the Cornerstone of the New Advanced Therapies Unit, Reaffirming its Global Leadership in this Field

The Sant Pau Research Institute celebrated today the laying of the cornerstone of its new Advanced Therapies Unit. These new facilities, supported by the Josep Carreras Leukaemia Research Institute and the Josep Carreras Foundation against Leukaemia, solidify themselves as a strategic resource for the Sant Pau Campus. They enable the development and manufacturing of personalized biological medicines within the hospital center for the treatment of its patients, reaffirming Sant Pau’s position as a global reference center in this field.

més…


Researchers at Sant Pau Identify a New Genetic Form of Alzheimer’s Disease

Researchers from the Research Area on Neurological Diseases, Neuroscience, and Mental Health at the Sant Pau Research Institute, led by Dr. Juan Fortea, Director of the Memory Unit of the Neurology Service at the same hospital, have found that over 95% of individuals over 65 years old who have two copies of the APOE4 gene -APOE4 homozygotes- show biological characteristics of Alzheimer’s pathology in the brain or biomarkers of this disease in cerebrospinal fluid and PET scans.

més…



A new research group on artificial intelligence applied to medicine is born at Sant Pau

The Sant Pau Research Institute announces the creation of the new research group in Advanced Medical Imaging, Artificial Intelligence, and Image-Guided Therapy. Dr. Josep Munuera, a researcher with a broad trajectory in the use of artificial intelligence applied to medicine and director of the Radiodiagnosis Service at Hospital Sant Pau, will lead this cross-sectional and multidisciplinary project that seeks to go beyond traditional specializations.

més…


Magnetic resonance surveillance reduces mortality in women at high risk of BRCA1 breast cancer as an alternative to preventive mastectomy

According to the results of an international study involving researchers from the Clinical Oncology group at the Sant Pau Research Institute, led by Dr. Teresa Ramon y Cajal, the follow-up with magnetic resonance imaging in women with mutations in the BRCA1 genes who have a high risk of developing breast cancer throughout their lives significantly reduces mortality without the need for preventive mastectomy.

més…


L’Institut de Recerca Sant Pau i el Banc de Sang i Teixits signen un acord per impulsar la recerca en teràpies avançades

L’Institut de Recerca Sant Pau (IR Sant Pau) i el Banc de Sang i Teixits (BST) han signat un acord de col·laboració destinat a impulsar el desenvolupament i la producció de medicaments innovadors.

L’acord, que representa una aliança pionera entre dues institucions capdavanteres en el camp de la salut, estableix les bases per a la creació d’un node conjunt que comptarà amb instal·lacions preparades per a la producció de teràpies avançades, incloent-hi les cèl·lules CAR-T.

més…


Deciphering Brain Connections between Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia

A group of scientists from various hospitals and research centers in Catalonia, led by Drs. Álvaro Carbayo and Ricard Rojas, researchers from the Neuromuscular Diseases Group at the Sant Pau Research Institute, in collaboration with Dr. Sergi Borrego-Écija and Dr. Ellen Gelpi from the Alzheimer’s Disease and other Cognitive Disorders Group and the Neurological Tissue Bank of IDIBAPS, have published a study in the journal Brain that reveals connections between two devastating brain diseases: Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia.

més…


Blood test diagnoses Alzheimer’s with over 90% accuracy

The detection of phosphorylated TAU 217 protein (p-tau217) in plasma has shown high precision in identifying pathological accumulations of beta-amyloid and TAU proteins. This precision is comparable to traditional biomarker detection in cerebrospinal fluid, as revealed by a recent study published in JAMA Neurology. Researchers from the Research Area in Neurological Diseases, Neuroscience, and Mental Health at the Sant Pau Research Institute, led by Dr. Juan Fortea, Director Sof the Memory Unit at the Neurology Department of the same hospital, participated in the study. These results pave the way for diagnosing Alzheimer’s disease through a blood test.

més…



Sant Pau receives 2.3 million euros from La Marató for cardiovascular disease research

La Marató de TV3 Foundation will fund 8 cardiovascular health projects coordinated from the Sant Pau Research Institute, thanks to the funds raised in the last edition, which was specifically dedicated to these diseases. In total, Sant Pau will receive €2,296,961.25, which will be allocated to leading projects on diseases such as myocardial infarction, stroke, atherosclerosis, hypercholesterolemia, or arrhythmias, some of them in collaboration with other research centers. Additionally, researchers from Sant Pau are also involved in two selected projects coordinated from other centers.

més…



Circulating microRNA could help predict and detect metastasis in early breast cancer

A study conducted at the Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau suggests that certain microRNAs (miRNAs) may be useful as non-invasive biomarkers for the early diagnosis of lymph node metastasis in patients with early-stage breast cancer. The research, led by Dr. Agustí Barnadas, head of the Clinical Oncology research group at IIB Sant Pau and head of the Medical Oncology service at the same hospital, focused on patients with early-stage breast cancer with estrogen receptor-positive (ER-positive) tumors.

més…


Deep Brain Stimulation Demonstrates Long-Term Benefits in Treatment-Resistant Depression Patients

A study conducted by researchers at the Research Institute from Hospital Santa Creu i Sant Pau – IIB Sant Pau in Barcelona, Spain, has shown that deep brain stimulation of the subcallosal cingulate gyrus (SCG-DBS) can offer significant and lasting benefits for treating depression. The results of this research support the idea that this surgical intervention could be an effective alternative for patients suffering from severe major depression who have not responded to conventional treatments.

més…



Sant Pau administrates a new CAR-T immunotherapy drug, self-produced, against B-cell lymphomas

The Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau has developed a new CAR-T 19 immunotherapy drug that has just begun to be administered, as part of a clinical trial, to patients with certain types of lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) who have not responded to other treatments. With this new and unique therapeutic proposal in Spain for these patients, Sant Pau offers its second academic advanced therapy medicinal product, which means that it has been entirely produced and developed at Sant Pau. This new CAR-T 19 is characterized by being enriched in memory T lymphocytes, which are longer-lasting over time, with the aim of having greater efficacy against the disease.

més…


A new tool using genomic and clinical data helps predicting the risk of thrombosis in cancer patients

Cancer patients are at high risk of suffering a thrombotic event that can worsen their prognosis and quality of life. Researchers from the Research Group on Genomics of Complex Diseases of the Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau, led by Dr. José Manuel Soria, and the Medical Oncology Service of the Gregorio Marañón General University Hospital in Madrid, led by Dr. Andrés Muñoz, within the framework of the Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM) have developed and validated a new tool or score, called ONCOTHROMB, which for the first time combines clinical data and genomics of the patient. This tool has shown an excellent predictive capacity of the risk of suffering venous thromboembolic events by cancer patients undergoing chemotherapy outpatient treatment.

més…



Identified two new genes that increases risk of Alzheimer’s disease

An international study in which researchers from the Dementia Neurobiology Group and the Memory Unit of the Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau participated, leaded by Alberto Lleó, discovered two new genes associated with a significantly increased risk of developing Alzheimer’s disease.

més…


This website uses cookies to improve the browsing experience and perform analytical tasks. If you continue browsing, we understand that you agree our cookies policy. More information